| Jan 13 2021 |
FDA Clarifies Food Traceability List Descriptions and Publishes Related FAQ |
Keller and Heckman LLP |
| Jan 13 2021 |
USDA Announces Intent to Transfer Regulatory Authority Over Animal Biotechnology from FDA to USDA |
Beveridge & Diamond PC |
| Jan 12 2021 |
FDA’s Action Plan for Artificial Intelligence: Highlights and Insights for Developers |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 12 2021 |
Preemption Torpedoes State Law Claims against Generics Makers in Zantac MDL |
Faegre Drinker |
| Jan 12 2021 |
WARNING: California Prop 65 Enforcement of THC Listing from CBD Products Became Effective January 3, 2021 |
Squire Patton Boggs (US) LLP |
| Jan 12 2021 |
China Approves New Food-Contact Materials: January 12, 2021 |
Keller and Heckman LLP |
| Jan 12 2021 |
Regulatory Yearly Wrap 2020: Medical Device in India |
Nishith Desai Associates |
| Jan 12 2021 |
2020 Advertising Law Year in Review |
Proskauer Rose LLP |
| Jan 12 2021 |
FDA Regulation of CBD Requires Filling “Knowledge Gaps” |
Keller and Heckman LLP |
| Jan 12 2021 |
Oregon Issues New Guidance on Hard Seltzer Classification |
McDermott Will & Schulte LLP |
| Jan 11 2021 |
Medi-Cal Rx: California to Transition Medi-Cal Pharmacy Benefits to Fee-For-Service |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 11 2021 |
HHS Advisory Opinion Concludes Manufacturers Must Deliver 340 B Drugs to Contract Pharmacies |
McDermott Will & Schulte LLP |
| Jan 11 2021 |
American Axle Petitions for Cert. |
Schwegman, Lundberg & Woessner, P.A. |
| Jan 11 2021 |
Regulatory Yearly Wrap 2020: Pharmaceuticals In India |
Nishith Desai Associates |
| Jan 11 2021 |
EPA Releases Late-Term “Secret Science” Rule |
ArentFox Schiff LLP |
| Jan 11 2021 |
California Proposes Limits on the “Short-Form” Warning Option under Proposition 65 |
Keller and Heckman LLP |
| Jan 11 2021 |
Proposed Regulatory Changes to Safe Harbor Warning Provisions |
Polsinelli PC |
| Jan 9 2021 |
Looking Ahead: FDA in 2021 |
Mintz |
| Jan 8 2021 |
Judges Toss Plain “Vanilla” Deceptive Labeling Claims |
Proskauer Rose LLP |
| Jan 8 2021 |
State of Ohio Board of Pharmacy Adopts Resolution Regarding Responsible Person Requirements for Licensure of Terminal Distributor and Dangerous Drugs License |
Dinsmore & Shohl LLP |
| Jan 8 2021 |
US-UK Equivalency Agreement for Organic Products Enters into Effect |
Keller and Heckman LLP |
| Jan 7 2021 |
National Advertising Division (NAD) Sides with Danone in Challenge of Chobani Comparative Sugar Claims |
Keller and Heckman LLP |
| Jan 6 2021 |
FDA Alerts Consumers to Pet Food Recalls for Potentially Fatal Levels of Aflatoxin |
Keller and Heckman LLP |
| Jan 5 2021 |
Drug Facility Fees Will Not Apply to Distilleries Producing Hand Sanitizer |
Bergeson & Campbell, P.C. |
| Jan 5 2021 |
Seventh Circuit Sides with Plaintiffs in Appeal of “100% Grated Parmesan Cheese” Claims |
Proskauer Rose LLP |
| Jan 5 2021 |
Improper CBD Product Marketing Lands in FDA’s Crosshairs |
Dinsmore & Shohl LLP |
| Jan 4 2021 |
FDA Adds Three New Substances to its Inventory of Effective FCS Notifications January 4 |
Keller and Heckman LLP |
| Jan 4 2021 |
FDA to Publish Biennial Uniform Compliance Date for 2021-2022 Food Labeling Regulations |
Keller and Heckman LLP |
| Jan 2 2021 |
Twelve Cannabis Plant Patents and Counting |
Squire Patton Boggs (US) LLP |
| Jan 1 2021 |
Federal Circuit Endorses the Doctrine of Equivalents Again for Lilly’s ALIMTA®: Different Amendment, Same Result |
Squire Patton Boggs (US) LLP |
| Dec 29 2020 |
Saga of “Most Favored Nations” |
Giordano, Halleran & Ciesla, P.C. |
| Dec 29 2020 |
Federal Courts Block Implementation of Most Favored Nation Drug Pricing Rule |
K&L Gates LLP |
| Dec 28 2020 |
Drug Testing Legislation in 2020: A Look Back |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Dec 27 2020 |
Digital Health in India: Emerging Technologies (AI and 3D printing) [Podcast] |
Nishith Desai Associates |
| Dec 25 2020 |
Intellectual Property Issues in the Indian Pharmaceutical Sector: Patents |
Nishith Desai Associates |
